Tesamorelin
Growth Hormone-Releasing Hormone (1-44) amide
Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog specifically indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It works by stimulating the pituitary gland to release growth hormone, leading to targeted reduction in visceral adipose tissue through enhanced lipolysis and fat metabolism.
Tesamorelin Mechanism of Action
The Complete Journey: From Injection to Results
Tesamorelin binds to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland, specifically on somatotroph cells. This binding activates adenylyl cyclase, increasing cyclic adenosine monophosphate (cAMP) levels, which stimulates the synthesis and release of endogenous growth hormone. The released growth hormone then binds to growth hormone receptors in adipose tissue, activating hormone-sensitive lipase and promoting lipolysis, particularly in visceral fat deposits.
How Tesamorelin Works at the Molecular Level
Scientific Mechanism
Tesamorelin binds to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland, specifically on somatotroph cells. This binding activates adenylyl cyclase, increasing cyclic adenosine monophosphate (cAMP) levels, which stimulates the synthesis and release of endogenous growth hormone. The released growth hormone then binds to growth hormone receptors in adipose tissue, activating hormone-sensitive lipase and promoting lipolysis, particularly in visceral fat deposits.
Simple Explanation
Think of tesamorelin as a messenger that tells your pituitary gland to release more growth hormone. Just like pressing a button that turns on a fat-burning machine, tesamorelin signals your brain to produce hormones that specifically target and break down stubborn belly fat. It's like having a key that unlocks your body's natural ability to reduce visceral fat through your own hormone system.
The Simple Truth: Why It Works So Well
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Tesamorelin (Egrifta) is an FDA-approved prescription medication that should only be used under the supervision of a qualified healthcare provider. Treatment requires proper patient selection, monitoring, and management of potential side effects. Patients must be evaluated for contraindications including active malignancy and diabetic complications. Regular monitoring of glucose levels, IGF-1, and treatment response is essential for safe and effective use.